Lyell Immunopharma Positioned for Potential Breakthrough with Aggressive Clinical Strategy

Lyell Immunopharma has initiated a pivotal Phase 3 clinical trial for its lead CAR T-cell therapy, marking a significant strategic move that positions the company to challenge established treatments in a multi-billion dollar market. The biotech firm’s decision to pursue a head-to-head comparison study represents one of the most ambitious approaches in the competitive oncology space.

The newly launched PiNACLE H2H study will evaluate Lyell’s dual-targeting CAR-T cell therapy, known as ronde-cel (LYL314), against two approved treatments: liso-cel and axi-cel. This comparative trial will focus on patients with relapsed or refractory large B-cell lymphoma, with enrollment of approximately 400 participants across clinical sites in the United States and Australia scheduled to commence in early 2026.

Notably, the study’s Read more...